Shares of Health Care sector company Biogen moved -2.5% today, and are now trading at a price of $286.59. The large-cap stock's daily volume was 510,315 compared to its average volume of 987,535. The S&P 500 index returned a -0.0% performance.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company is based in Cambridge and has 8,725 full time employees. Its market capitalization is $41,481,609,216.
27 analysts are following Biogen and have set target prices ranging from $263.0 to $398.0 per share. On average, they have given the company a rating of buy. At today's prices, BIIB is trading -14.6% away from its average analyst target price of $335.59 per share.
Over the last year, BIIB's share price has increased by 38.7%, which represents a difference of 27.0% when compared to the S&P 500. The stock's 52 week high is $319.76 per share whereas its 52 week low is $193.65. Biogen's average free cash flow over the last 4 years has been $3.7 Billion, but they have been decreasing at an average rate of -31.8%. This may prove a challenge to the long term sustainability of the stock's upwards trend.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 1,384,300 | -243,200 | 1,384,300 | -58.62 |
| 2021-12-31 | 3,639,900 | -294,900 | 3,345,000 | -9.05 |
| 2020-12-31 | 4,229,800 | -551,800 | 3,678,000 | -42.61 |
| 2019-12-31 | 7,078,600 | -669,500 | 6,409,100 | n/a |
